The Effect of Nintedanib on T-Cell Activation, Subsets and Functions
Kenia Ubieta, Matthew James Thomas, Lutz Wollin Immunology & Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, GermanyCorrespondence: Lutz WollinBoehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, Biberach, 88397, GermanyTel +49 7351 54-9499...
Saved in:
Main Authors: | Ubieta K (Author), Thomas MJ (Author), Wollin L (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
by: Bonella F, et al.
Published: (2015) -
Clinical development of nintedanib for advanced non-small-cell lung cancer
by: Takeda M, et al.
Published: (2015) -
Dysregulation of Mesenchymal Cell Survival Pathways in Severe Fibrotic Lung Disease: The Effect of Nintedanib Therapy
by: Rajesh K. Kasam, et al.
Published: (2019) -
Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
by: Woodcock HV, et al.
Published: (2013) -
Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
by: Lin T, et al.
Published: (2017)